摘要目的 探讨三阴性乳腺癌(TNBC)中间质肿瘤浸润淋巴细胞(TIL)和CD8+、FOXP3+的淋巴细胞亚型与临床病理参数的相关性.方法 收集南京医科大学第一附属医院2012-2014年病理资料完整的女性TNBC标本160例,均为未经化疗和放疗的手术切除或穿刺组织,经常规石蜡包埋制片,判读HE染色切片间质TIL百分比,采用免疫组织化学MaxVision法检测160例TNBC病例中间质CD8+、FOXP3+淋巴细胞浸润密度.结果 乳腺癌间质TIL与Ki-67呈正相关(P=0.002);CD8+细胞毒T细胞(CTL)浸润密度与肿瘤大小呈负相关(P =0.009),与Ki-67呈正相关(P=0.021);FOXP3+调节性T细胞与患者年龄呈负相关(P =0.030),与组织学分级呈正相关(P=0.026);间质TIL与CD8+CTL呈正相关(P=0.014).结论 TNBC中间质TIL百分比、CD8+CTL浸润密度可能与乳腺癌的增殖相关,FOXP3+调节性T细胞浸润密度可能与乳腺癌不良预后相关,间质TIL与CD8+CTL浸润密度呈正相关.间质TIL可能成为TNBC临床病理诊断、辅助治疗的新靶点.

abstractsObjective To investigate the relationship between stromal tumor-infiltrating lymphocytes (TIL) and CD8 or FOXP3 positive lymphocytes in triple-negative breast carcinoma.Methods A total of 160 triple-negative breast carcinomas were collected from the First Affiliated Hospital of Nanjing Medical University during 2012 to 2014.All were surgical excision or biopsy specimens from patients without prior chemotherapy and radiotherapy.Histopathologic analysis of stromal TIL was performed on hematoxylin and eosin-stained sections,and MaxVision immunohistochemical method was used for detection of CD8 and FOXP3 protein expression.Results Stromal TILs were positively correlated with Ki-67 labeling index (P =0.002).The density of CD8 + cytotoxic T-lymphocyte (CTL) was negatively correlated with tumor size (P =0.009),and positively correlated with Ki-67 index (P =0.021).The density of FOXP3 + regulatory T-lymphocyte (Treg) was inversely correlated with the patient age (P =0.030),and positively correlated with histological grade (P =0.026).Stromal TILs were positively correlated with the density of CD8 + CTL (P =0.014).Conclusions The percentage of stromal TILs and density of CD8 + CTL are associated with tumor cell proliferation of triple-negative breast cancers.The density of FOXP3 + Treg is significantly associated with poor prognosis.Stromal TIL is positively correlated with the density of CD8 + CTL Stromal TIL may provide a potential marker for pathological diagnosis and a target for guiding adjuvant therapy in patients with triple-negative breast cancers.